A majority of nicotinamide mononucleotide (NMN) supplements on the market are failing independent purity testing, and one brand is responding with batch-level transparency rarely seen in the finished-supplement channel. Element 5 has announced it now publishes five independent laboratory reports for every NMN production batch, with its most recent round returning 100.7% purity by high-performance liquid chromatography (HPLC) and an average fill weight of 522 mg per capsule.

The backdrop is sobering for the NAD+ precursor category. Independent quality audits have flagged 64% of commercially available NMN supplements as failing purity benchmarks — a figure that underscores long-standing quality-control gaps in the broader supplement market. NMN, which has seen rapid consumer adoption on the strength of preclinical and emerging clinical data linking NAD+ restoration to cellular energy metabolism and longevity pathways, commands a premium price point that makes mislabeled or underfilled products a significant consumer harm.

Why Five Reports Matter

The five-report protocol goes beyond the single certificate of analysis (COA) that most brands display on product pages. By commissioning multiple independent assays per batch, Element 5 is structuring its quality program around both identity verification and quantitative dose confirmation — two distinct analytical endpoints that a single COA may not fully cover. HPLC is the industry standard for quantifying active-molecule concentration, and a 100.7% purity result indicates essentially no degradation or contaminating analogues at the point of batch release. The 522 mg average fill weight likewise confirms that capsule dosing aligns with label claims, addressing a common failure mode — underfilling — that shows up repeatedly in third-party market audits.

For formulators and contract manufacturers sourcing NMN for white-label or branded finished goods, batch-level documentation of this depth also de-risks regulatory exposure. Structure-function claims on NAD+ precursor products depend on the delivered dose matching the studied dose; a gap between label claim and actual fill weight can undermine both the clinical rationale and any future FDA scrutiny of marketing language.

Category Stakes

The NMN and broader NAD+ precursor category has attracted significant investment from supplement brands, direct-to-consumer longevity platforms, and ingredient suppliers over the past five years. Consumer search interest in NMN has remained elevated alongside parallel interest in related compounds such as NR (nicotinamide riboside), driven by research from institutions including the University of Washington and multiple peer-reviewed publications examining NAD+ decline with age. That scientific momentum has drawn quality-focused operators into the space — but it has also attracted lower-cost entrants whose manufacturing controls lag the category's clinical ambitions.

Element 5's decision to publish every batch report publicly, rather than making documentation available only on request, positions the brand as a transparency benchmark at a moment when quality differentiation is increasingly a purchase driver for the informed supplement consumer. Retail buyers and e-commerce platforms evaluating NMN SKUs now have a documented quality standard against which to compare supplier claims — a dynamic that tends to accelerate category-wide quality improvement over time.

Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.

Frequently Asked Questions

What exactly is Element 5 doing differently with its COA protocol?

Element 5 publishes five independent laboratory reports per batch instead of the single COA most competitors rely on. This dual-endpoint approach verifies both identity and quantitative dose, with their latest batch hitting 100.7% purity by HPLC and 522 mg average fill weight—essentially eliminating the underfilling and degradation that plague 64% of competing NMN products.

Why should my innovation team care about the 64% failure rate?

Your customers are paying $1.50–$3.00 per gram for NMN, and two-thirds of the market is delivering subpotent or contaminated product. If you're formulating or sourcing NMN, a failed batch from a competitor signals risk to your own supply chain and consumer trust—especially as NAD+ precursors scale into mainstream wellness.

What does 100.7% purity actually tell a buyer?

HPLC quantification at 100.7% means zero detectable degradation, isomers, or synthesis byproducts at release. That's the ceiling for chemical purity and confirms the batch wasn't oxidized, stored improperly, or cut with filler—red flags that show up constantly in third-party audits of the NMN category.

Is a single COA from a brand's own lab sufficient?

No. A single in-house or captive-lab COA leaves blind spots: it covers potency but not necessarily fill weight, and it doesn't rule out batch-to-batch variance or storage degradation post-analysis. Independent, multi-method testing catches underfilling, contamination, and drift that a single snapshot report will miss.

How do I evaluate NMN suppliers now?

Ask for batch-level COAs from independent third parties (not the brand's own lab), verify HPLC quantification above 99%, and confirm fill-weight data on capsules. If a supplier refuses transparency or offers only a single COA, that's a disqualifier—the market baseline has shifted, and Element 5's protocol is now the de facto standard.